J Cancer 2011; 2:142-152. doi:10.7150/jca.2.142
An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development
1. Division of Hematology/Oncology;
2. Department of Laboratory Medicine and Pathology;
3. Department of Cancer Biology;
4. Department of Diagnostic Radiology, Mayo Clinic, Jacksonville, Florida, USA;
5. The Translational Genomics Research Institute (TGen), Phoenix AZ, USA;
6. Highlands Oncology Group, Bentonville AR, USA.
Armstrong MD, Von Hoff D, Barber B, Marlow LA, von Roemeling C, Cooper SJ, Travis P, Campbell E, Paz-Fumagalli R, Copland JA, Colon-Otero G. An Effective Personalized Approach to a Rare Tumor: Prolonged Survival in Metastatic Pancreatic Acinar Cell Carcinoma Based on Genetic Analysis and Cell Line Development. J Cancer 2011; 2:142-152. doi:10.7150/jca.2.142. Available from http://www.jcancer.org/v02p0142.htm
Acinar cell carcinoma of the pancreas is an uncommon malignancy, accounting for less than 1% of all pancreatic neoplasms. Because of its rarity, only a few retrospective studies are available to help guide management. We report the case of a patient with metastatic ACC who achieved prolonged survival as a result of personalized treatment designed in part on the basis of molecular and in-vitro data collected on analysis of the tumor and a cell line developed from the liver metastasis. To our knowledge, this represents the first human cell line of ACC. The molecular findings on this case and this patient's cell line may be of use in the management of future cases of this rare tumor and allow the identification of potential novel targets for the effective treatment of this disease.
Keywords: acinar cell pancreatic cancer, prolonged survival, personalized medicine, cell line